{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-26-003545","form_type":"8-K","ticker":"CNXU","cik":"0002066836","company_name":"Conexeu Sciences Inc.","filed_at":"2026-07-07T21:12:57+00:00","discovered_at":"2026-07-07T21:14:00.568087+00:00","generated_at":"2026-07-07T21:14:11.578241+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Conexeu Sciences completes 12-month preclinical P.R.O.O.F study for CXU platform","bullets":["12-month preclinical study met objectives for tissue restoration in cheek and 200cc-equivalent models.","CXU platform met injectability and volumizing performance benchmarks for aesthetic injectables.","GLP-1 weight-loss drug market projected to reach ~$190B by 2035, driving tissue-restoration gap to $2B by 2030.","Company plans predicate-based 510(k) submission for wound care in Q1 2027, targeting 90-day FDA review.","Patent estate spans over 40 jurisdictions including U.S., EU, Japan, and Australia."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-003545","json":"https://secwatch.observer/filing/0001062993-26-003545.json","markdown":"https://secwatch.observer/filing/0001062993-26-003545.md","text":"https://secwatch.observer/filing/0001062993-26-003545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2066836/000106299326003545/0001062993-26-003545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2066836/000106299326003545/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T21:14:11.578241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}